Takeda Drops Phase II Diabetes Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Compound fails to measure up to exisiting treatments, firm says.
You may also be interested in...
Actos Patent Expiry Fuels Takeda’s Drive For Deals – Licensing Exec
During BIO-Asia 2007 in Tokyo, Takeda’s head of licensing outlines the strategy behind the company’s deal with Affymax.
Actos Patent Expiry Fuels Takeda’s Drive For Deals – Licensing Exec
During BIO-Asia 2007 in Tokyo, Takeda’s head of licensing outlines the strategy behind the company’s deal with Affymax.
Actos Patent Expiry Fuels Takeda's Drive For Deals - Licensing Exec
Takeda is looking to partner with companies owning late-stage compounds in an effort to replace revenue that will likely be lost following U.S. patent expiry of its blockbuster type 2 diabetes treatment Actos (pioglitazone), according to General Manager of Global Licensing & Business Development Hiroaki Ogata
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: